SOHO 2023 Eleventh Annual Meeting
M

SOHO 2023: Emerging BCL2 Inhibitors

By SOHO 2023 Eleventh Annual Meeting FEATURING Mary Ann Anderson
By SOHO 2023 Eleventh Annual Meeting FEATURING Mary Ann Anderson
0 views
November 21, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Recommended

AUTOPLAY
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi